A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors
This is an, open-label, multi-center, three-part phase I trial to evaluate the safety, pharmacokinetics and immunogenicity of SHR-1909 and preliminary anti-tumor efficacy of SHR-1909 in advanced malignant cancer.
Advanced Malignant Cancer
DRUG: SHR-1909 injection
MTD of SHR-1909, Maximum tolerated dose (MTD) based on dose-limiting toxicities (DLTs), From Day 1 to 4 weeks|RP2D of SHR-1909, Recommended Phase 2 Dose(RP2D) of SHR-1909 will be determined during the dose-escalation and dose-expansion parts of the study. RP2D will be determined using available safety, pharmacokinetics and pharmacodynamics data., From Day 1 to 90 days after last dose
Adverse Events, Adverse Events documented by CTCAE 5.0, 90 days after the last dose|Objective Response Rate (ORR), Baseline to documented disease progression or study discontinuation, Up to approximately 2 years|Progression-Free Survival (PFS), From Day 1 to Radiographic Progression or Death Due to Any Cause, Up to approximately 2 years
This is an, open-label, multi-center, three-part phase I trial to evaluate the safety, pharmacokinetics and immunogenicity of SHR-1909 and preliminary anti-tumor efficacy of SHR-1909 in advanced malignant cancer.